Michael Lillestol

5.5k total citations · 1 hit paper
8 papers, 1.0k citations indexed

About

Michael Lillestol is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Michael Lillestol has authored 8 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Surgery, 3 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Michael Lillestol's work include Bone health and treatments (2 papers), Pharmacological Effects and Toxicity Studies (2 papers) and Bone health and osteoporosis research (2 papers). Michael Lillestol is often cited by papers focused on Bone health and treatments (2 papers), Pharmacological Effects and Toxicity Studies (2 papers) and Bone health and osteoporosis research (2 papers). Michael Lillestol collaborates with scholars based in United States, United Kingdom and Canada. Michael Lillestol's co-authors include David L. Kendler, Suresh Siddhanti, Christian Roux, Claude Laurent Benhamou, Jacques P. Brown, Henry G. Bone, Javier San Martín, Lesley Burgess, Eli M. Roth and Maria Laura Monsalvo and has published in prestigious journals such as New England Journal of Medicine, Journal of Bone and Mineral Research and American Journal of Kidney Diseases.

In The Last Decade

Michael Lillestol

7 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

2014 553 citations Dirk Blom, Tomas Hala et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Michael Lillestol

Since Specialization

Citations

This map shows the geographic impact of Michael Lillestol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lillestol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lillestol more than expected).

Fields of papers citing papers by Michael Lillestol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lillestol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lillestol. The network helps show where Michael Lillestol may publish in the future.

Co-authorship network of co-authors of Michael Lillestol

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lillestol. A scholar is included among the top collaborators of Michael Lillestol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lillestol. Michael Lillestol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment 2024 ·Endocrine Practice ·Elena A. Christofides, Andrzej Stankiewicz, Douglas Denham, Diego Bellido, Edward Franek, Samer Nakhle, Monika Łukaszewicz, John H. Reed, (unknown), (unknown), (unknown), David Fitzpatrick, (unknown), Mark Warren, Priscilla Hollander, David Huffman, Philip Raskin, Tamás Oroszlán, Michael Lillestol, Fernando Ovalle	0
2	Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT) 2016 ·American Journal of Kidney Diseases ·Joseph G. Verbalis, Howard Ellison, Mary Hobart, Holly B. Krasa, John Ouyang, Frank S. Czerwiec, (unknown), (unknown), Miguel Franco, (unknown), (unknown), (unknown), Ali Khojasteh, (unknown), Michael Lillestol, (unknown), David P. Rosenbaum, Mitchell H. Rosner, (unknown), (unknown)	42
3	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia breakdown → 2014 ·New England Journal of Medicine ·Dirk Blom, Tomas Hala, Michael A. Bolognese, Michael Lillestol, Phillip D. Toth, Lesley Burgess, R Češka, Eli M. Roth, Michael J. Koren, Christie M. Ballantyne, Maria Laura Monsalvo, Kate Tsirtsonis, Jae Bum Kim, Robert C. Scott, Scott M. Wasserman, Evan A. Stein	553
4	Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study 2013 ·Menopause The Journal of The North American Menopause Society ·David L. Kendler, David Macarios, Michael Lillestol, Alfred H. Moffett, Sacha Satram‐Hoang, (unknown), Primal Kaur, En‐Tzu Tang, Rachel B. Wagman, Rob Horne	25
5	Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy With Hydrochlorothiazide Monotherapy in Older Patients With Stage 2 Systolic Hypertension: Results of the ACTION Study 2011 ·Journal of Clinical Hypertension ·Jan Basile, (unknown), Michael Lillestol, Jaco Botha, (unknown), Richard E. Weitzman	9
6	Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate 2010 ·Osteoporosis International ·(unknown), David L. Kendler, Michael R. McClung, Nick Freemantle, Michael Lillestol, Alfred H. Moffett, Jeff Borenstein, Sacha Satram‐Hoang, Yuching Yang, Primal Kaur, David Macarios, Suresh Siddhanti	84
7	FIRST-LINE ALISKIREN/HYDROCHLOROTHIAZIDE COMBINATION THERAPY LOWERS BLOOD PRESSURE MORE EFFECTIVELY THAN HYDROCHLOROTHIAZIDE ALONE IN OBESE OLDER PATIENTS WITH STAGE 2 HYPERTENSION: PP.34.376 2010 ·Journal of Hypertension ·Jan Basile, (unknown), Michael Lillestol, (unknown), (unknown), Richard E. Weitzman	2
8	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy 2009 ·Journal of Bone and Mineral Research ·David L. Kendler, Christian Roux, Claude Laurent Benhamou, Jacques P. Brown, Michael Lillestol, Suresh Siddhanti, (unknown), Javier San Martín, Henry G. Bone	322

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact